$ACUT
Accustem Sciences Inc.

2022 Q3 Form 10-Q Financial Statement

#000149315222022218 Filed on August 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $840.0K
YoY Change
% of Gross Profit
Research & Development $58.27K $54.40K $21.14K
YoY Change 312.53% 80.13%
% of Gross Profit
Depreciation & Amortization $907.00 $830.00 $677.00
YoY Change
% of Gross Profit
Operating Expenses $899.1K $1.078M $790.5K
YoY Change 1333.51% 2033.54%
Operating Profit -$899.1K -$1.078M -$790.5K
YoY Change 1333.51% 2033.54%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$899.1K -$1.078M -$790.5K
YoY Change 1333.51% 2033.54%
Income Tax
% Of Pretax Income
Net Earnings -$899.1K -$1.078M -$790.5K
YoY Change 1333.51% 2033.54%
Net Earnings / Revenue
Basic Earnings Per Share -$0.08 -$0.10 -$0.08
Diluted Earnings Per Share -$0.08 -$0.10
COMMON SHARES
Basic Shares Outstanding 11.34M shares 11.34M shares 10.03M shares
Diluted Shares Outstanding 11.34M shares 11.34M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.332M
YoY Change
Cash & Equivalents $1.332M $1.982M $3.245M
Short-Term Investments
Other Short-Term Assets $282.1K
YoY Change
Inventory
Prepaid Expenses $282.1K $391.0K
Receivables
Other Receivables
Total Short-Term Assets $1.614M $2.372M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $8.585K $9.492K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $8.585K $9.492K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.614M $2.372M
Total Long-Term Assets $8.585K $9.492K
Total Assets $1.623M $2.382M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $154.9K $109.0K
YoY Change
Accrued Expenses $349.2K $218.3K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $212.1K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $824.9K $731.4K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $824.9K $731.4K
Total Long-Term Liabilities $0.00
Total Liabilities $824.9K $731.4K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$3.493M -$2.594M
YoY Change
Common Stock $11.35K $11.34K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $797.7K $1.651M $2.691M
YoY Change
Total Liabilities & Shareholders Equity $1.623M $2.382M
YoY Change

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$899.1K -$1.078M -$790.5K
YoY Change 1333.51% 2033.54%
Depreciation, Depletion And Amortization $907.00 $830.00 $677.00
YoY Change
Cash From Operating Activities -$1.315M $372.0K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures $11.00K $8.203K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$11.00K -$8.203K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.658M $2.881M
YoY Change
NET CHANGE
Cash From Operating Activities -1.315M $372.0K
Cash From Investing Activities -11.00K -$8.203K
Cash From Financing Activities 2.658M $2.881M
Net Change In Cash 1.332M $3.245M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$1.315M $372.0K
Capital Expenditures $11.00K $8.203K
Free Cash Flow -$1.326M $363.8K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Depreciation
Depreciation
usd
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
shares
dei Entity Central Index Key
EntityCentralIndexKey
0001850767
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Depreciation
Depreciation
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
ACUT Proceeds From Receipt Of Subscription Receivable
ProceedsFromReceiptOfSubscriptionReceivable
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
us-gaap Notes Issued1
NotesIssued1
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56257
dei Entity Registrant Name
EntityRegistrantName
ACCUSTEM SCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-3774438
dei Entity Address Address Line1
EntityAddressAddressLine1
5 Penn Plaza
dei Entity Address Address Line2
EntityAddressAddressLine2
19th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
#1954 New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10001
dei City Area Code
CityAreaCode
00 44
dei Local Phone Number
LocalPhoneNumber
2074952379
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
ACUT
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11337571 shares
CY2022Q2 us-gaap Cash
Cash
1981510 usd
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
1353373 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
390954 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
2372464 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1353373 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9492 usd
CY2022Q2 us-gaap Assets
Assets
2381956 usd
CY2021Q4 us-gaap Assets
Assets
1353373 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
108961 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
388681 usd
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
87599 usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
190838 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
218303 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
123181 usd
CY2022Q2 us-gaap Notes Payable Current
NotesPayableCurrent
316527 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
731390 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
702700 usd
CY2022Q2 us-gaap Liabilities
Liabilities
731390 usd
CY2021Q4 us-gaap Liabilities
Liabilities
702700 usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11337571 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11337571 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9999132 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9999132 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
11337 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
9999 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4232851 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1503434 usd
CY2021Q4 ACUT Subscription Receivable Related Party
SubscriptionReceivableRelatedParty
-204879 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1868760 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-64410 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50138 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1868760 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
66981 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2593622 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-724862 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1650566 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
650673 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2381956 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1353373 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54396 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30198 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
75539 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32815 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1023830 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20339 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1793221 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31595 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
1078226 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
50537 usd
us-gaap Operating Expenses
OperatingExpenses
1868760 usd
us-gaap Operating Expenses
OperatingExpenses
64410 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1078226 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-50537 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1078226 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-50537 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1868760 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-64410 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1078226 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-50537 usd
us-gaap Net Income Loss
NetIncomeLoss
-1868760 usd
us-gaap Net Income Loss
NetIncomeLoss
-64410 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11337107 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9999132 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10682986 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9999132 shares
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1078226 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-50537 usd
us-gaap Net Income Loss
NetIncomeLoss
-1868760 usd
us-gaap Net Income Loss
NetIncomeLoss
-64410 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-399 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-17081 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1078226 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47329 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2691017 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
37588 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
187 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1078226 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1650566 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1310338 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
406 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-50537 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
1260207 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
650673 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
54628 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2675940 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
204879 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
187 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-66981 usd
us-gaap Net Income Loss
NetIncomeLoss
-1868760 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1650566 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1309796 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1309796 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
14821 usd
us-gaap Net Income Loss
NetIncomeLoss
-64410 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
1260207 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
1260207 usd
us-gaap Net Income Loss
NetIncomeLoss
-1868760 usd
us-gaap Net Income Loss
NetIncomeLoss
-64410 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
66981 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-14815 usd
us-gaap Depreciation
Depreciation
1507 usd
us-gaap Share Based Compensation
ShareBasedCompensation
54628 usd
ACUT Increase Decrease In Related Party Receivable
IncreaseDecreaseInRelatedPartyReceivable
1353373 usd
ACUT Increase Decrease In Related Party Receivable
IncreaseDecreaseInRelatedPartyReceivable
-14959 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-48168 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-279720 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
51015 usd
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
103239 usd
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-13075 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
96278 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
464 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-764746 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10999 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10999 usd
ACUT Proceeds From Receipt Of Subscription Receivable
ProceedsFromReceiptOfSubscriptionReceivable
204879 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2676127 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
123751 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2757255 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1981510 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1981510 usd
us-gaap Notes Issued1
NotesIssued1
439122 usd
us-gaap Interest Paid Net
InterestPaidNet
1503 usd
us-gaap Net Income Loss
NetIncomeLoss
-1868760 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2593622 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_zpNVzIMHrnCe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z5K3lu8giTHl">Use of Estimates</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2022Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022Q1 us-gaap Investments
Investments
2765940 usd
CY2022Q1 us-gaap Investments
Investments
2000000 gbp
CY2022Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1337970 shares
CY2022Q2 us-gaap Notes Payable
NotesPayable
321760 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10999 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1507 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9492 usd
CY2022Q2 us-gaap Depreciation
Depreciation
830 usd
CY2021Q2 us-gaap Depreciation
Depreciation
0 usd
us-gaap Depreciation
Depreciation
1507 usd
ACUT Licensee Fund
LicenseeFund
50000 gbp
ACUT Licensee Fund
LicenseeFund
55408 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1078226 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-50537 usd
us-gaap Net Income Loss
NetIncomeLoss
-1868760 usd
us-gaap Net Income Loss
NetIncomeLoss
-64410 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1078226 usd
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-50537 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1868760 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-64410 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11337107 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9999132 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10682986 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9999132 shares
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
173517 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
173517 shares
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
100005 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.42
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0154 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0234 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.572 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.657 pure
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
942781 usd
CY2022Q2 us-gaap Related Party Costs
RelatedPartyCosts
22087 usd
CY2021Q2 us-gaap Related Party Costs
RelatedPartyCosts
3154 usd
us-gaap Related Party Costs
RelatedPartyCosts
26447 usd
us-gaap Related Party Costs
RelatedPartyCosts
6179 usd

Files In Submission

Name View Source Status
0001493152-22-022218-index-headers.html Edgar Link pending
0001493152-22-022218-index.html Edgar Link pending
0001493152-22-022218.txt Edgar Link pending
0001493152-22-022218-xbrl.zip Edgar Link pending
acut-20220630.xsd Edgar Link pending
acut-20220630_cal.xml Edgar Link unprocessable
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
form10q_001.jpg Edgar Link pending
form10q_002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
acut-20220630_lab.xml Edgar Link unprocessable
acut-20220630_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
acut-20220630_def.xml Edgar Link unprocessable